New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs BPC-157

PNC-27 vs BPC-157

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Recovery & Repair
BPC-157
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in the stomach. It is one of the most extensively researched healing peptides, known for accelerating tissue repair, reducing inflammation, and protecting the gastrointestinal tract.
Half-Life
Not well established; estimated minutes to hours
4–6 hours
Admin Route
Intravenous (research), Intraperitoneal (research)
SubQ, IM, Oral
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
200–500 mcg
Frequency
Not established for human use
Once daily
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Accelerates wound healing and tissue repair
  • Reduces inflammation throughout the body
  • Protects and heals the gastrointestinal tract
  • Supports tendon and ligament healing
  • Promotes bone and joint health
  • May protect organs from toxins and injury
  • Supports gut-brain axis function
  • Counteracts NSAID-induced gut damage
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Injection site discomfort
  • Nausea (rare)
  • Headache (rare)
  • Dizziness (rare)
Stacks With